A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Participants With ER+/HER2- Locally Advanced or Metastatic Breast Cancer (mBC)
Et klinisk fase 1/2, åbent mærke, dosiseskalering og kohorteudvidelse til evaluering af sikkerheden, tolerabiliteten og farmakokinetikken af ARV-471 alene og i kombination med Palbociclib (IBRANCE®) hos patienter med østrogenreceptorpositiv/human epidermal vækst Faktor Receptor 2 Negativ (ER+/HER2-) lokalt avanceret eller metastatisk brystkræft, som har modtaget forudgående hormonbehandling og kemoterapi i lokalt avanceret/metastatisk indstilling
This was a Phase 1/2 dose escalation and cohort expansion study and assessed the safety, tolerability and anti-tumor activity of ARV-471 alone and in combination with palbociclib (IBRANCE®) in participants with estrogen receptor positive/human epidermal growth factor receptor 2 negative (ER+/HER2-) locally advanced or mBC, who had received prior hormonal therapy and chemotherapy in the locally advanced/metastatic setting.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Faktiske)
Tilmelding
Fase
Fase
- Fase 2
- Fase 1
Kontakter og lokationer
Studiesteder
-
-
California
-
Palo Alto, California, Forenede Stater, 94304
- Clinical Trial Site
-
San Francisco, California, Forenede Stater, 94158
- Clinical Trial Site
-
Santa Monica, California, Forenede Stater, 90404
- Clinical Trial Site
-
-
Connecticut
-
Norwalk, Connecticut, Forenede Stater, 06856
- Clinical Trial Site
-
-
Florida
-
Fort Myers, Florida, Forenede Stater, 33901
- Clinical Trial Site
-
Tampa, Florida, Forenede Stater, 33612
- Clinical Trial Site
-
-
Illinois
-
Chicago, Illinois, Forenede Stater, 60637
- Clinical Trial Site
-
-
Massachusetts
-
Boston, Massachusetts, Forenede Stater, 02114
- Clinical Trial Site
-
Boston, Massachusetts, Forenede Stater, 02215
- Clinical Trial Site
-
-
Michigan
-
Ann Arbor, Michigan, Forenede Stater, 48109
- Clinical Trial Site
-
-
Missouri
-
St Louis, Missouri, Forenede Stater, 63110
- Clinical Trial Site
-
-
New Jersey
-
East Brunswick, New Jersey, Forenede Stater, 08816
- Clinical Trial Site
-
-
New York
-
The Bronx, New York, Forenede Stater, 10461
- Clinical Trial Site
-
-
North Carolina
-
Charlotte, North Carolina, Forenede Stater, 28204
- Clinical Trial Site
-
-
Tennessee
-
Nashville, Tennessee, Forenede Stater, 37203
- Clinical Trial Site
-
-
Washington
-
Seattle, Washington, Forenede Stater, 98109
- Clinical Trial Site
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
Part A, Part B, and Part C:
- Participants at least 18 years of age at the time of signing the informed consent.
- Participants must have histologically or cytologically confirmed ER+ and HER2- advanced breast cancer for which standard curative therapy is no longer effective or does not exist.
- Participants must have measurable or non-measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) (version1.1), with radiologic tumor assessments performed within 28 days of the first dose of therapy.
- Participants must be willing to undergo a core biopsy of accessible tumor within 4 weeks prior to the initiation of study treatment and a follow-up biopsy on treatment for ER immunohistochemistry (IHC) testing and pharmacodynamics studies. (Patients without accessible tumor tissue may be eligible after discussion with the Medical Monitor.)
- Women must be postmenopausal due to surgical or natural menopause.
Part A:
- Participants must have received at least 2 prior endocrine regimens in any setting (neoadjuvant, adjuvant or advanced/metastatic) a CDK4/6 inhibitor and up to 3 prior regimens of cytotoxic chemotherapy in the locally advanced or metastatic setting.
Part B:
- Participants must have received at least 1 prior endocrine regimen for a minimum of 6 months in the locally advanced or metastatic setting; if more than 1 prior endocrine regimen has been administered, only one of the regimens must have been administered for a minimum of 6 months in the locally advanced or metastatic setting
- Participants must have received a CDK4/6 inhibitor
- Participants must have received up to 1 prior regimen of cytotoxic chemotherapy in the locally advanced or metastatic setting
Part C:
- Participants must have received at least one prior endocrine regimen.
- Participants must have received no more than two prior chemotherapy regimens for advanced disease.
Exclusion Criteria:
Part A, Part B, and Part C:
- Participants with known symptomatic brain metastases requiring steroids (above physiologic replacement doses). Patients with previously diagnosed brain metastases are eligible if they have completed their treatment and have recovered from the acute effects of radiation therapy or surgery prior to first dose of study drug, have discontinued high-dose corticosteroid treatment for these metastases for at least 4 weeks and are neurologically stable as judged by the Investigator.
- Receipt of prior anti-cancer or other investigational therapy within 14 days prior to the first administration of study drug.
- Radiation therapy within 4 weeks of first dose of study drug or prior irradiation to >25% of the bone marrow. Palliative radiation for the alleviation of pain due to bone metastasis will be allowed during the study.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomiseret
- Interventionel model: Sekventiel tildeling
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Part A - Phase 1: Vepdegestrant 30 mg (Dose Escalation)
Participants received vepdegestrant 30 milligrams (mg) orally once daily (QD) with food in continuous daily dosing (on 28-day cycles). Vepdegestrant was administered in tablet form. Treatment was continued at the investigator's discretion until disease progression, unacceptable toxicity, or withdrawal of consent occurred. Participants were followed for survival every 3 months after the end of treatment (EOT) or Follow-up visit (whichever occurred later) until death, lost to follow-up, or withdrawal of consent. |
Vepdegestrant administered QD for 28-day cycles
Andre navne:
Vepdegestrant administered QD or BID for 28-day cycles.
Andre navne:
|
|
Eksperimentel: Part A - Phase 1: Vepdegestrant 60 mg (Dose Escalation)
Participants received vepdegestrant 60 mg orally QD with food in continuous daily dosing (on 28-day cycles). Vepdegestrant was administered in tablet form. Treatment was continued at the investigator's discretion until disease progression, unacceptable toxicity, or withdrawal of consent occurred. Participants were followed for survival every 3 months after EOT or Follow-up visit (whichever occurred later) until death, lost to follow-up, or withdrawal of consent. |
Vepdegestrant administered QD for 28-day cycles
Andre navne:
Vepdegestrant administered QD or BID for 28-day cycles.
Andre navne:
|
|
Eksperimentel: Part A - Phase 1: Vepdegestrant 100 mg (Dose Escalation)
Participants received vepdegestrant 100 mg orally QD with food in continuous daily dosing (on 28-day cycles). Vepdegestrant was administered in tablet form. Treatment was continued at the investigator's discretion until disease progression, unacceptable toxicity, or withdrawal of consent occurred. Participants were followed for survival every 3 months after EOT or Follow-up visit (whichever occurred later) until death, lost to follow-up, or withdrawal of consent. |
Vepdegestrant administered QD for 28-day cycles
Andre navne:
Vepdegestrant administered QD or BID for 28-day cycles.
Andre navne:
|
|
Eksperimentel: Part A - Phase 1: Vepdegestrant 120 mg (Dose Escalation)
Participants received vepdegestrant 120 mg orally QD with food in continuous daily dosing (on 28-day cycles). Vepdegestrant was administered in tablet form. Treatment was continued at the investigator's discretion until disease progression, unacceptable toxicity, or withdrawal of consent occurred. Participants were followed for survival every 3 months after EOT or Follow-up visit (whichever occurred later) until death, lost to follow-up, or withdrawal of consent. |
Vepdegestrant administered QD for 28-day cycles
Andre navne:
Vepdegestrant administered QD or BID for 28-day cycles.
Andre navne:
|
|
Eksperimentel: Part A - Phase 1: Vepdegestrant 180 mg (Dose Escalation)
Participants received vepdegestrant 180 mg orally QD with food in continuous daily dosing (on 28-day cycles). Vepdegestrant was administered in tablet form. Treatment was continued at the investigator's discretion until disease progression, unacceptable toxicity, or withdrawal of consent occurred. Participants were followed for survival every 3 months after EOT or Follow-up visit (whichever occurred later) until death, lost to follow-up, or withdrawal of consent. |
Vepdegestrant administered QD for 28-day cycles
Andre navne:
Vepdegestrant administered QD or BID for 28-day cycles.
Andre navne:
|
|
Eksperimentel: Part A - Phase 1: Vepdegestrant 200 mg (Dose Escalation)
Participants received vepdegestrant 200 mg orally QD with food in continuous daily dosing (on 28-day cycles). Vepdegestrant was administered in tablet form. Treatment was continued at the investigator's discretion until disease progression, unacceptable toxicity, or withdrawal of consent occurred. Participants were followed for survival every 3 months after EOT or Follow-up visit (whichever occurred later) until death, lost to follow-up, or withdrawal of consent. |
Vepdegestrant administered QD for 28-day cycles
Andre navne:
Vepdegestrant administered QD or BID for 28-day cycles.
Andre navne:
|
|
Eksperimentel: Part A - Phase 1: Vepdegestrant 360 mg (Dose Escalation)
Participants received vepdegestrant 360 mg orally QD with food in continuous daily dosing (on 28-day cycles). Vepdegestrant was administered in tablet form. Treatment was continued at the investigator's discretion until disease progression, unacceptable toxicity, or withdrawal of consent occurred. Participants were followed for survival every 3 months after EOT or Follow-up visit (whichever occurred later) until death, lost to follow-up, or withdrawal of consent. |
Vepdegestrant administered QD for 28-day cycles
Andre navne:
Vepdegestrant administered QD or BID for 28-day cycles.
Andre navne:
|
|
Eksperimentel: Part A - Phase 1: Vepdegestrant 500 mg (Dose Escalation)
Participants received vepdegestrant 500 mg QD or 250 mg twice daily (BID), orally with food in continuous daily dosing (on 28-day cycles). Vepdegestrant was administered in tablet form. Treatment was continued at the investigator's discretion until disease progression, unacceptable toxicity, or withdrawal of consent occurred. Participants were followed for survival every 3 months after EOT or Follow-up visit (whichever occurred later) until death, lost to follow-up, or withdrawal of consent. |
Vepdegestrant administered QD for 28-day cycles
Andre navne:
Vepdegestrant administered QD or BID for 28-day cycles.
Andre navne:
|
|
Eksperimentel: Part A - Phase 1: Vepdegestrant 700 mg (Dose Escalation)
Participants received vepdegestrant 700 mg QD or as BID dose (400 mg in the morning and 300 mg in the evening), orally with food in continuous daily dosing (on 28-day cycles). Vepdegestrant was administered in tablet form. Treatment was continued at the investigator's discretion until disease progression, unacceptable toxicity, or withdrawal of consent occurred. Participants were followed for survival every 3 months after EOT or Follow-up visit (whichever occurred later) until death, lost to follow-up, or withdrawal of consent. |
Vepdegestrant administered QD for 28-day cycles
Andre navne:
Vepdegestrant administered QD or BID for 28-day cycles.
Andre navne:
|
|
Eksperimentel: Part B - Phase 2: Vepdegestrant 200 mg (Dose Expansion)
Participants received vepdegestrant 200 mg orally QD with food in continuous daily dosing (on 28-day cycles). Vepdegestrant was administered in tablet form. Treatment was continued at the investigator's discretion until disease progression, unacceptable toxicity, or withdrawal of consent occurred. Participants were followed for survival every 3 months after EOT or Follow-up visit (whichever occurred later) until death, lost to follow-up, or withdrawal of consent. |
Vepdegestrant administered QD for 28-day cycles
Andre navne:
Vepdegestrant administered QD or BID for 28-day cycles.
Andre navne:
|
|
Eksperimentel: Part B - Phase 2: Vepdegestrant 500 mg (Dose Expansion)
Participants received vepdegestrant 500 mg orally QD with food in continuous daily dosing (on 28-day cycles). Vepdegestrant was administered in tablet form. Treatment was continued at the investigator's discretion until disease progression, unacceptable toxicity, or withdrawal of consent occurred. Participants were followed for survival every 3 months after EOT or Follow-up visit (whichever occurred later) until death, lost to follow-up, or withdrawal of consent. |
Vepdegestrant administered QD for 28-day cycles
Andre navne:
Vepdegestrant administered QD or BID for 28-day cycles.
Andre navne:
|
|
Eksperimentel: Part C - Phase 1b: Vepdegestrant 180 mg+ Palbociclib 125 mg (Dose Escalation)
Participants initially received vepdegestrant 180 mg tablets orally QD with food then upon availability of the 100-mg tablets was rounded up to 200 mg QD, given continuously (28-day cycle) in combination with palbociclib 125 mg orally QD for 21 days followed by 7 days off treatment to complete a 28-day cycle. Vepdegestrant was administered in tablet form and palbociclib in capsule form. Treatment was continued at the investigator's discretion until disease progression, unacceptable toxicity, or withdrawal of consent occurred. Participants were followed up for survival after at least 3 months after the EOT or Follow-up visit (whichever occurred later). |
Vepdegestrant administered QD for 28-day cycles
Andre navne:
Vepdegestrant administered QD or BID for 28-day cycles.
Andre navne:
Daily oral dosages of vepdegestrant for 28 days in combination with palbociclib for 21 days
Andre navne:
|
|
Eksperimentel: Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 125 mg (Dose Expansion)
Participants received vepdegestrant 200 mg orally QD with food, given continuously (28-day cycle) in combination with palbociclib 125 mg orally QD for 21 days followed by 7 days off treatment to complete a 28-day cycle. Vepdegestrant was administered in tablet form and palbociclib in capsule form. Treatment was continued at the investigator's discretion until disease progression, unacceptable toxicity, or withdrawal of consent occurred. Participants were followed for survival every 3 months after EOT or Follow-up visit (whichever occurred later) until death, lost to follow-up, or withdrawal of consent. |
Vepdegestrant administered QD for 28-day cycles
Andre navne:
Vepdegestrant administered QD or BID for 28-day cycles.
Andre navne:
Daily oral dosages of vepdegestrant for 28 days in combination with palbociclib for 21 days
Andre navne:
|
|
Eksperimentel: Part C - Phase 1b: Vepdegestrant 400 mg + Palbociclib 125 mg (Dose Escalation)
Participants received vepdegestrant 400 mg orally QD with food, given continuously (28-day cycle) in combination with palbociclib 125 mg orally QD for 21 days followed by 7 days off treatment to complete a 28-day cycle. Vepdegestrant was administered in tablet form and palbociclib in capsule form. Treatment was continued at the investigator's discretion until disease progression, unacceptable toxicity, or withdrawal of consent occurred. Participants were followed for survival every 3 months after EOT or Follow-up visit (whichever occurred later) until death, lost to follow-up, or withdrawal of consent. |
Vepdegestrant administered QD for 28-day cycles
Andre navne:
Vepdegestrant administered QD or BID for 28-day cycles.
Andre navne:
Daily oral dosages of vepdegestrant for 28 days in combination with palbociclib for 21 days
Andre navne:
|
|
Eksperimentel: Part C - Phase 1b: Vepdegestrant 500 mg + Palbociclib 125 mg (Dose Expansion)
Participants received vepdegestrant 500 mg orally QD with food, given continuously (28-day cycle) in combination with palbociclib 125 mg orally QD for 21 days followed by 7 days off treatment to complete a 28-day cycle. Vepdegestrant was administered in tablet form and palbociclib in capsule form. Treatment was continued at the investigator's discretion until disease progression, unacceptable toxicity, or withdrawal of consent occurred. Participants were followed for survival every 3 months after EOT or Follow-up visit (whichever occurred later) until death, lost to follow-up, or withdrawal of consent. |
Vepdegestrant administered QD for 28-day cycles
Andre navne:
Vepdegestrant administered QD or BID for 28-day cycles.
Andre navne:
Daily oral dosages of vepdegestrant for 28 days in combination with palbociclib for 21 days
Andre navne:
|
|
Eksperimentel: Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 100 mg (Dose Expansion)
Participants initially received palbociclib 100 mg orally QD starting on C1D1, for 21 days followed by 7 days off and then received vepdegestrant 200 mg QD with food on C1D9, given continuously (28-day cycle). Palbociclib was administered alone from C1D1 to C1D8 prior to starting vepdegestrant on C1D9. Vepdegestrant was administered in tablet form and palbociclib in capsule form. Treatment was continued at the investigator's discretion until disease progression, unacceptable toxicity, or withdrawal of consent occurred. Participants were followed for survival every 3 months after EOT or follow-up visit (whichever occurred later) until death, lost to follow-up, or withdrawal of consent. |
Vepdegestrant administered QD for 28-day cycles
Andre navne:
Vepdegestrant administered QD or BID for 28-day cycles.
Andre navne:
Daily oral dosages of vepdegestrant for 28 days in combination with palbociclib for 21 days
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Part A: Number of Participants With Dose Limiting Toxicities (DLTs) During First Cycle of Treatment
Tidsramme: Baseline (Day 1) up to C1D28
|
DLT was defined as any adverse event (AE) or abnormal laboratory value which were related to vepdegestrant and assessed as unrelated to mBC, intercurrent illness, or concomitant medications occurring during the first 28 days of treatment that met at least 1 of the study specified criteria. |
Baseline (Day 1) up to C1D28
|
|
Part A: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs and Treatment-Related TEAEs
Tidsramme: From start of study treatment up to 30 days after end of study treatment (up to approximately 4 years and 6 months)
|
An AE is any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. Treatment-related AE was any untoward medical occurrence attributed to study treatment in a participant who received study treatment. Relatedness was judged by investigator. Serious AE (SAE) was an AE resulted in any of the following outcomes: death, inpatient hospitalization or prolongation of existing hospitalization; was life-threatening experience (immediate risk of dying); resulted in persistent or significant disability/incapacity; congenital anomaly/birth defect or was otherwise considered medically important. A TEAE was an AE occurring on/after the date of first dose of study medication and within 30 days of the last dose of study medication. TEAEs included both Serious TEAEs and non-serious TEAEs. |
From start of study treatment up to 30 days after end of study treatment (up to approximately 4 years and 6 months)
|
|
Part B: Clinical Benefit Rate (CBR)
Tidsramme: From start of study treatment until disease progression or death due to any cause (up to approximately 2 years and 11 months)
|
CBR: percentage of participants with summation of complete response (CR), partial response (PR) or stable disease (SD) of 24 weeks duration or longer. CR: disappearance of all target lesions (TLs) and non-TLs and normalization of tumor marker levels initially above upper limits of normal. PR: >30% decrease in the sum of the longest diameter (LD) of TLs, taking as reference the baseline sum LD. SD of TLs was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum LD since the treatment started. SD of non-TLs Persistence of one or more non-TLs or/and maintenance of tumor marker level above the normal limits. PD: >20% increase in the sum of the LD of TLs, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non-TLs. |
From start of study treatment until disease progression or death due to any cause (up to approximately 2 years and 11 months)
|
|
Part C: Number of Participants With Dose Limiting Toxicities (DLTs) During First Cycle of Treatment
Tidsramme: Baseline (Day 1) up to C1D28
|
DLT was defined as any AE or abnormal laboratory value which were related to vepdegestrant and assessed as unrelated to mBC, intercurrent illness, or concomitant medications occurring during the first 28 days of treatment that met at least 1 of the study specified criteria. |
Baseline (Day 1) up to C1D28
|
|
Part C: Number of Participants With TEAEs, Serious TEAEs and Treatment-Related TEAEs
Tidsramme: From start of study treatment up to 30 days after end of study treatment (up to approximately 3 years and 9 months)
|
An AE is any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. Treatment-related AE was any untoward medical occurrence attributed to study treatment in a participant who received study treatment. Relatedness was judged by investigator. SAE was an AE resulted in any of the following outcomes: death, inpatient hospitalization or prolongation of existing hospitalization; was life-threatening experience (immediate risk of dying); resulted in persistent or significant disability/incapacity; congenital anomaly/birth defect or was otherwise considered medically important. A TEAE was an AE occurring on/after the date of first dose of study medication and within 30 days of the last dose of study medication. TEAEs included both Serious TEAEs and non-serious TEAEs. |
From start of study treatment up to 30 days after end of study treatment (up to approximately 3 years and 9 months)
|
|
Part C: Maximum Tolerated Dose (MTD)
Tidsramme: Baseline (Day 1) up to C1D28
|
MTD is the highest dose of a drug that can be given to participants without causing unacceptable DLTs, as determined during a clinical study. |
Baseline (Day 1) up to C1D28
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Part A: Area Under the Concentration-Time Curve During a Dosing Interval (AUCtau) of Vepdegestrant and Its Epimer ARV-473
Tidsramme: Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D1 and C1D15, and an additional sample at 24 hours post dose on C1D1.
|
AUCtau was defined as area under the concentration-time curve during a dosing interval calculated by linear up/log down trapezoidal summation. Based on predefined reporting convention in the SAP, summary statistics describing variability (standard deviation/geometric coefficient of variation) were not calculated or presented for analysis groups or timepoints if fewer than 3 participants had reportable parameter values. |
Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D1 and C1D15, and an additional sample at 24 hours post dose on C1D1.
|
|
Part A: Area Under the Concentration-time Curve From Time 0 Through the Last Measurable Concentration (AUClast) of Vepdegestrant and Its Epimer ARV-473
Tidsramme: Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D1 and C1D15, and an additional sample at 24 hours post dose on C1D1
|
AUClast was defined as area under the concentration-time curve from time 0 through the last quantifiable concentration (AUClast). Based on predefined reporting convention in the SAP, summary statistics describing variability (standard deviation/geometric coefficient of variation) were not calculated or presented for analysis groups or timepoints if fewer than 3 participants had reportable parameter values. |
Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D1 and C1D15, and an additional sample at 24 hours post dose on C1D1
|
|
Part A: Maximum Observed Plasma Concentration (Cmax) of Vepdegestrant and Its Epimer ARV-473
Tidsramme: Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D1 and C1D15, and an additional sample at 24 hours post dose on C1D1
|
Cmax was defined as the maximum observed plasma concentration obtained directly from the observed concentration versus time data. Based on predefined reporting convention in the SAP, summary statistics describing variability (standard deviation/geometric coefficient of variation) were not calculated or presented for analysis groups or timepoints if fewer than 3 participants had reportable parameter values. |
Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D1 and C1D15, and an additional sample at 24 hours post dose on C1D1
|
|
Part A: Minimum Observed Plasma Concentration (Cmin) of Vepdegestrant and Its Epimer ARV- 473
Tidsramme: Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D15
|
Cmin was defined as the minimum observed plasma concentration. Based on predefined reporting convention in the SAP, summary statistics describing variability (standard deviation/geometric coefficient of variation) were not calculated or presented for analysis groups or timepoints if fewer than 3 participants had reportable parameter values. |
Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D15
|
|
Part A: Apparent Oral Plasma Clearance (CL/F) of Vepdegestrant
Tidsramme: Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D15
|
CL/F was defined as the apparent oral plasma clearance of vepdegestrant. Based on predefined reporting convention in the SAP, summary statistics describing variability (standard deviation/geometric coefficient of variation) were not calculated or presented for analysis groups or timepoints if fewer than 3 participants had reportable parameter values. |
Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D15
|
|
Part A: Time of Maximum Observed Plasma Concentration (Tmax) of Vepdegestrant and Its Epimer ARV- 473
Tidsramme: Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D1 and C1D15, and an additional sample at 24 hours post dose on C1D1
|
Tmax was defined as the time of maximum observed plasma concentration. Based on predefined reporting convention in the SAP, summary statistics describing variability (median) was not calculated or presented for analysis groups or timepoints if fewer than 3 participants had reportable parameter values. |
Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D1 and C1D15, and an additional sample at 24 hours post dose on C1D1
|
|
Part A: Accumulation Ratio for AUC0-tau (Rac [AUCtau]) of Vepdegestrant and Its Epimer ARV- 473
Tidsramme: Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D1 and C1D15, and an additional sample at 24 hours post dose on C1D1
|
Rac was calculated as the ratio of Day 15/Day 1 based on AUCtau. AUCtau was defined as area under the concentration-time curve during a dosing interval calculated by linear up/log down trapezoidal summation. Based on predefined reporting convention in the SAP, summary statistics describing variability (standard deviation/geometric coefficient of variation) were not calculated or presented for analysis groups or timepoints if fewer than 3 participants had reportable parameter values. |
Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D1 and C1D15, and an additional sample at 24 hours post dose on C1D1
|
|
Part A: Accumulation Ratio for Cmax (Rac [Cmax]) of Vepdegestrant and Its Epimer ARV- 473
Tidsramme: Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D1 and C1D15, and an additional sample at 24 hours post dose on C1D1
|
Rac was calculated as the ratio of Day 15/Day 1 based on Cmax. Cmax was defined as the maximum observed plasma concentration obtained directly from the observed concentration versus time data. Based on predefined reporting convention in the SAP, summary statistics describing variability (standard deviation/geometric coefficient of variation) were not calculated or presented for analysis groups or timepoints if fewer than 3 participants had reportable parameter values. |
Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D1 and C1D15, and an additional sample at 24 hours post dose on C1D1
|
|
Part A: Effective Half-life Based on Accumulation Ratio of RAUC(0-tau) of Vepdegestrant and Its Epimer ARV-473
Tidsramme: Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D1 and C1D15, and an additional sample at 24 hours post dose on C1D1
|
Effective half-life based on accumulation ratio of RAUC(0-tau). Accumulation ratio was calculated as the ratio of Day 15/Day 1 based on AUCtau. AUCtau was defined as area under the concentration-time curve during a dosing interval calculated by linear up/log down trapezoidal summation. Based on predefined reporting convention in the SAP, summary statistics describing variability (standard deviation/geometric coefficient of variation) were not calculated or presented for analysis groups or timepoints if fewer than 3 participants had reportable parameter values. |
Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D1 and C1D15, and an additional sample at 24 hours post dose on C1D1
|
|
Part A: Epimer (ARV-473) to Parent (Vepdegestrant) Ratio for Cmax (MRCmax).
Tidsramme: Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D1 and C1D15, and an additional sample at 24 hours post dose on C1D1
|
The epimer ARV-473 to parent ratio based on Cmax was reported. Cmax was defined as the maximum observed plasma concentration obtained directly from the observed concentration versus time data. Based on predefined reporting convention in the SAP, summary statistics describing variability (standard deviation/geometric coefficient of variation) were not calculated or presented for analysis groups or timepoints if fewer than 3 participants had reportable parameter values. |
Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D1 and C1D15, and an additional sample at 24 hours post dose on C1D1
|
|
Part A: Epimer (ARV-473) to Parent (Vepdegestrant) Ratio for AUCtau (MRAUCtau)
Tidsramme: Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D1 and C1D15, and an additional sample at 24 hours post dose on C1D1
|
The epimer ARV-473 to parent ratio based on AUCtau was reported. AUCtau was defined as area under the concentration-time curve during a dosing interval calculated by linear up/log down trapezoidal summation. Based on predefined reporting convention in the SAP, summary statistics describing variability (standard deviation/geometric coefficient of variation) were not calculated or presented for analysis groups or timepoints if fewer than 3 participants had reportable parameter values. |
Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D1 and C1D15, and an additional sample at 24 hours post dose on C1D1
|
|
Part A: Overall Response Rate (ORR) by Investigator Per RECIST v1.1
Tidsramme: From start of study treatment until disease progression or death due to any cause (up to approximately 4 years and 6 months)
|
ORR was defined as the percentage of participants with best overall response (BOR) of CR and PR as per Response Evaluation Criteria in Solid Tumours (RECIST version [v] 1.1). BOR: best response was recorded from start of study treatment until disease progression or death due to any cause. CR was defined as disappearance of all TLs and non-TLs and normalization of tumor marker levels initially above upper limits of normal. PR was defined as >30% decrease in the sum of the LD of TLs, taking as reference the baseline sum LD. PD: >20% increase in the sum of the LD of TLs, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non-TLs. Only participants with measurable disease at baseline were included in the analysis of ORR. |
From start of study treatment until disease progression or death due to any cause (up to approximately 4 years and 6 months)
|
|
Part A: Clinical Benefit Rate (CBR)
Tidsramme: From start of study treatment until disease progression or death due to any cause (up to approximately 4 years and 6 months)
|
CBR: percentage of participants with summation of CR, PR or SD of 24 weeks duration or longer. CR: disappearance of all TLs and non-TLs and normalization of tumor marker levels initially above upper limits of normal. PR: >30% decrease in the sum of the LD of TLs, taking as reference the baseline sum LD. SD of TLs was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started. SD of non-TLs Persistence of one or more non-TLs or/and maintenance of tumor marker level above the normal limits. PD: >20% increase in the sum of the LD of TLs, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non-TLs. |
From start of study treatment until disease progression or death due to any cause (up to approximately 4 years and 6 months)
|
|
Part A: Disease Control Rate (DCR)
Tidsramme: From start of study treatment up to progressive disease or death (up to approximately 4 years and 6 months)
|
DCR: percentage of participants with CR, PR or SD. CR: disappearance of all TLs and non-TLs and normalization of tumor marker levels initially above upper limits of normal. PR: >30% decrease in the sum of the LD of TLs, taking as reference the baseline sum LD. SD of TLs was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started. SD of non-TLs Persistence of one or more non-TLs or/and maintenance of tumor marker level above the normal limits. PD: >20% increase in the sum of the LD of TLs, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non-TLs. DCR was based on confirmed responses. Confirmed responses were at least 4 weeks after the criteria for response were first met. |
From start of study treatment up to progressive disease or death (up to approximately 4 years and 6 months)
|
|
Part A: Progression-Free Survival (PFS) Per RECIST v1.1
Tidsramme: From start of study treatment up to progressive disease or death (up to approximately 4 years and 6 months)
|
PFS: time from first dose of the study drug until date of documented radiological PD based on RECIST V1.1, or until death due to any cause, whichever occurred first. PD: >20% increase in the sum of the LD of TLs, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non-TLs. Kaplan-Meier (KM) estimate was used for analysis. |
From start of study treatment up to progressive disease or death (up to approximately 4 years and 6 months)
|
|
Part A: Duration of Response
Tidsramme: From the date of first documented confirmed CR/PR to the date of PD or death due to any cause (up to approximately 4 years and 6 months)
|
DOR was defined as the time interval from the date of first documented confirmed CR/PR to the date of PD or death, whichever occurred first per RECIST version v 1.1. CR: disappearance of all TLs and non-TLs and normalization of tumor marker levels initially above upper limits of normal. PR: >30% decrease in the sum of the LD of TLs, taking as reference the baseline sum LD. PD: >20% increase in the sum of the LD of TLs, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non-TLs. KM estimate was used for analysis. |
From the date of first documented confirmed CR/PR to the date of PD or death due to any cause (up to approximately 4 years and 6 months)
|
|
Part B: Overall Response Rate (ORR) by Investigator Per RECIST v1.1
Tidsramme: From start of study treatment until disease progression or death due to any cause (up to approximately 2 years and 11 months)
|
ORR was defined as the percentage of participants with BOR of CR and PR as per RECIST version [v] 1.1. BOR: best response was recorded from start of study treatment until disease progression or death due to any cause. CR was defined as disappearance of all TLs and non-TLs and normalization of tumor marker levels initially above upper limits of normal. PR was defined as >30% decrease in the sum of the LD of TLs, taking as reference the baseline sum LD. PD: >20% increase in the sum of the LD of TLs, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non-TLs. Only participants with measurable disease at baseline were included in the analysis of ORR. |
From start of study treatment until disease progression or death due to any cause (up to approximately 2 years and 11 months)
|
|
Part B: Progression-Free Survival (PFS) Per RECIST v1.1
Tidsramme: From start of study treatment up to progressive disease or death (up to approximately 2 years and 11 months)
|
PFS: time from first dose of the study drug until date of documented radiological PD based on RECIST V1.1, or until death due to any cause, whichever occurred first. PD: >20% increase in the sum of the LD of TLs, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non-TLs. KM estimate was used for analysis. |
From start of study treatment up to progressive disease or death (up to approximately 2 years and 11 months)
|
|
Part B: Duration of Response
Tidsramme: From the date of first documented confirmed CR/PR to the date of PD or death due to any cause (up to approximately 2 years and 11 months)
|
DOR was defined as the time interval from the date of first documented confirmed CR/PR to the date of PD or death, whichever occurred first per RECIST version v 1.1. CR: disappearance of all TLs and non-TLs and normalization of tumor marker levels initially above upper limits of normal. PR: >30% decrease in the sum of the LD of TLs, taking as reference the baseline sum LD. PD: >20% increase in the sum of the LD of TLs, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non-TLs. KM estimate was used for analysis. |
From the date of first documented confirmed CR/PR to the date of PD or death due to any cause (up to approximately 2 years and 11 months)
|
|
Part B: Overall Survival
Tidsramme: From start of study treatment up to death (up to approximately 2 years and 11 months)
|
OS was defined as the time from first dose of the study drug until the documented date of death from any cause. KM estimate was used for analysis. |
From start of study treatment up to death (up to approximately 2 years and 11 months)
|
|
Part B: Number of Participants With TEAEs, Serious TEAEs and Treatment-Related TEAEs
Tidsramme: From start of study treatment up to 30 days after end of study treatment (up to approximately 2 years and 11 months)
|
An AE is any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. Treatment-related AE was any untoward medical occurrence attributed to study treatment in a participant who received study treatment. Relatedness was judged by investigator. SAE was an AE resulted in any of the following outcomes: death, inpatient hospitalization or prolongation of existing hospitalization; was life-threatening experience (immediate risk of dying); resulted in persistent or significant disability/incapacity; congenital anomaly/birth defect or was otherwise considered medically important. A TEAE was an AE occurring on/after the date of first dose of study medication and within 30 days of the last dose of study medication. TEAEs included both Serious TEAEs and non-serious TEAEs. |
From start of study treatment up to 30 days after end of study treatment (up to approximately 2 years and 11 months)
|
|
Part B: Pre-dose Concentrations of Vepdegestrant and Its Epimer ARV-473
Tidsramme: Predose on C1D15 and C1D28 to C26D28
|
Pre-dose Plasma concentrations of vepdegestrant and ARV-473 was reported. Based on predefined reporting convention in the SAP, summary statistics describing variability (standard deviation/geometric coefficient of variation) were not calculated or presented for analysis groups or timepoints if fewer than 3 participants had reportable parameter values. |
Predose on C1D15 and C1D28 to C26D28
|
|
Part C: Area Under the Concentration-Time Curve During a Dosing Interval (AUCtau) of Vepdegestrant, Its Epimer ARV-473 and Palbociclib
Tidsramme: Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D1 and C1D15, and an additional sample at 24 hours post dose on C1D1 for palbociclib 125 mg arms. Pre-dose, 1, 2, 4, 6, 8 hours post dose on C1D8, C1D21/C2D15 for palbociclib 100 mg arms.
|
AUCtau was calculated by linear up/log down trapezoidal summation. As planned for Part C, PK data of vepdegestrant & ARV-473 and palbociclib for arms administered with 125 mg palbociclib was reported for C1D1 and C1D15. PK data of vepdegestrant & ARV-473 data for arm administered with 100 mg palbociclib was reported for combined C1D21 and C2D15, and palbociclib PK data for C1D8 and combined C1D21 and C2D15. As per protocol, in the arm administered with 100 mg palbociclib, if the intensive PK sample collection was not done on C1D21, it was postponed to C2D15. Only combined data on C1D21 and C2D15 represented all the data at the steady state of the combination of vepdegestrant 200 mg QD with palbociclib and were used for drug-drug interaction (DDI) evaluation. Based on predefined reporting convention in the SAP, summary statistics were not calculated or presented for analysis groups or timepoints if fewer than 3 participants had reportable parameter values. |
Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D1 and C1D15, and an additional sample at 24 hours post dose on C1D1 for palbociclib 125 mg arms. Pre-dose, 1, 2, 4, 6, 8 hours post dose on C1D8, C1D21/C2D15 for palbociclib 100 mg arms.
|
|
Part C: Area Under the Concentration-time Curve From Time 0 Through the Last Measurable Concentration (AUClast) of Vepdegestrant, Its Epimer ARV-473 and Palbociclib
Tidsramme: Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D1 and C1D15, and an additional sample at 24 hours post dose on C1D1 for palbociclib 125 mg arms. Pre-dose, 1, 2, 4, 6, 8 hours post dose on C1D8, C1D21/C2D15 for palbociclib 100 mg arms.
|
As planned for Part C, PK data of vepdegestrant and ARV-473 and palbociclib for arms administered with 125 mg palbociclib was reported for C1D1 and C1D15. PK data of vepdegestrant and ARV-473 data for arm administered with 100 mg palbociclib was reported for combined C1D21 and C2D15, and palbociclib PK data for C1D8 and combined C1D21 and C2D15. As per protocol, in the arm administered with 100 mg palbociclib, if the intensive PK sample collection was not done on C1D21, it was postponed to C2D15. Only combined data on C1D21 and C2D15 represented all the data at the steady state of the combination of vepdegestrant 200 mg QD with palbociclib and were used for DDI evaluation. Based on predefined reporting convention in the SAP, summary statistics were not calculated or presented for analysis groups or timepoints if fewer than 3 participants had reportable parameter values. |
Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D1 and C1D15, and an additional sample at 24 hours post dose on C1D1 for palbociclib 125 mg arms. Pre-dose, 1, 2, 4, 6, 8 hours post dose on C1D8, C1D21/C2D15 for palbociclib 100 mg arms.
|
|
Part C: Maximum Observed Plasma Concentration (Cmax) of Vepdegestrant, Its Epimer ARV-473 and Palbociclib
Tidsramme: Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D1 and C1D15, and an additional sample at 24 hours post dose on C1D1 for palbociclib 125 mg arms. Pre-dose, 1, 2, 4, 6, 8 hours post dose on C1D8, C1D21/C2D15 for palbociclib 100 mg arms.
|
As planned for Part C, PK data of vepdegestrant and ARV-473 and palbociclib for arms administered with 125 mg palbociclib was reported for C1D1 and C1D15. PK data of vepdegestrant and ARV-473 data for arm administered with 100 mg palbociclib was reported for combined C1D21 and C2D15, and palbociclib PK data for C1D8 and combined C1D21 and C2D15. As per protocol, in the arm administered with 100 mg palbociclib, if the intensive PK sample collection was not done on C1D21, it was postponed to C2D15. Only combined data on C1D21 and C2D15 represented all the data at the steady state of the combination of vepdegestrant 200 mg QD with palbociclib and were used for DDI evaluation. Based on predefined reporting convention in the SAP, summary statistics were not calculated or presented for analysis groups or timepoints if fewer than 3 participants had reportable parameter values. |
Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D1 and C1D15, and an additional sample at 24 hours post dose on C1D1 for palbociclib 125 mg arms. Pre-dose, 1, 2, 4, 6, 8 hours post dose on C1D8, C1D21/C2D15 for palbociclib 100 mg arms.
|
|
Part C: Minimum Observed Plasma Concentration (Cmin) of Vepdegestrant, Its Epimer ARV-473 and Palbociclib
Tidsramme: Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D15 for arms with palbociclib 125 mg. Pre-dose, 1, 2, 4, 6, 8 hours post dose on C1D8, C1D21/C2D15 for arm with palbociclib 100 mg.
|
Cmin was defined as the minimum observed plasma concentration. As planned for Part C, PK data of vepdegestrant and ARV-473 and palbociclib for arms administered with 125 mg palbociclib was reported for C1D15. PK data of vepdegestrant and ARV-473 data for arm administered with 100 mg palbociclib was reported for combined C1D21 and C2D15, and palbociclib PK data for C1D8 and combined C1D21 and C2D15. As per protocol, in the arm administered with 100 mg palbociclib, if the intensive PK sample collection was not done on C1D21, it was postponed to C2D15. Only combined data on C1D21 and C2D15 represented all the data at the steady state of the combination of vepdegestrant 200 mg QD with palbociclib and were used for DDI evaluation. Based on predefined reporting convention in the SAP, summary statistics were not calculated or presented for analysis groups or timepoints if fewer than 3 participants had reportable parameter values. |
Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D15 for arms with palbociclib 125 mg. Pre-dose, 1, 2, 4, 6, 8 hours post dose on C1D8, C1D21/C2D15 for arm with palbociclib 100 mg.
|
|
Part C: Apparent Oral Plasma Clearance (CL/F) of Vepdegestrant and Palbociclib
Tidsramme: Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D15 for arms with palbociclib 125 mg. Pre-dose, 1, 2, 4, 6, 8 hours post dose on C1D8, C1D21/C2D15 for arm with palbociclib 100 mg.
|
As planned for Part C, PK data of vepdegestrant and palbociclib for arms administered with 125 mg palbociclib was reported for C1D15. PK data of vepdegestrant data for arm administered with 100 mg palbociclib was reported for combined C1D21 and C2D15, and palbociclib PK data for C1D8 and combined C1D21 and C2D15. As per protocol, in the arm administered with 100 mg palbociclib, if the intensive PK sample collection was not done on C1D21, it was postponed to C2D15. Only combined data on C1D21 and C2D15 represented all the data at the steady state of the combination of vepdegestrant 200 mg QD with palbociclib and were used for DDI evaluation. Based on predefined reporting convention in the SAP, summary statistics were not calculated or presented for analysis groups or timepoints if fewer than 3 participants had reportable parameter values. |
Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D15 for arms with palbociclib 125 mg. Pre-dose, 1, 2, 4, 6, 8 hours post dose on C1D8, C1D21/C2D15 for arm with palbociclib 100 mg.
|
|
Part C: Time of Maximum Observed Plasma Concentration (Tmax) of Vepdegestrant, Its Epimer ARV-473 and Palbociclib
Tidsramme: Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D1 and C1D15, and an additional sample at 24 hours post dose on C1D1 for palbociclib 125 mg arms. Pre-dose, 1, 2, 4, 6, 8 hours post dose on C1D8, C1D21/C2D15 for palbociclib 100 mg arms.
|
Tmax was defined as the time of maximum observed plasma concentration. As planned for Part C, PK data of vepdegestrant and ARV-473 and palbociclib for arms administered with 125 mg palbociclib was reported for C1D1 and C1D15. PK data of vepdegestrant and ARV-473 data for arm administered with 100 mg palbociclib was reported for combined C1D21 and C2D15, and palbociclib PK data for C1D8 and combined C1D21 and C2D15. As per protocol, in the arm administered with 100 mg palbociclib, if the intensive PK sample collection was not done on C1D21, it was postponed to C2D15. Only combined data on C1D21 and C2D15 represented all the data at the steady state of the combination of vepdegestrant 200 mg QD with palbociclib and were used for DDI evaluation. Based on predefined reporting convention in the SAP, summary statistics were not calculated or presented for analysis groups or timepoints if fewer than 3 participants had reportable parameter values. |
Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D1 and C1D15, and an additional sample at 24 hours post dose on C1D1 for palbociclib 125 mg arms. Pre-dose, 1, 2, 4, 6, 8 hours post dose on C1D8, C1D21/C2D15 for palbociclib 100 mg arms.
|
|
Part C: Accumulation Ratio for AUC0-tau (Rac [AUCtau]) of Vepdegestrant, Its Epimer ARV-473 and Palbociclib
Tidsramme: Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D1 and C1D15, and an additional sample at 24 hours post dose on C1D1 for palbociclib 125 mg arms.
|
Rac was calculated as the ratio of Day 15/Day 1 based on AUCtau. AUCtau was defined as area under the concentration-time curve during a dosing interval calculated by linear up/log down trapezoidal summation. As planned for Part C, PK data of vepdegestrant and ARV-473 and palbociclib for arms administered with 125 mg palbociclib was reported for C1D1 and C1D15. As prespecified, participants in the Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 100 mg Arm were not assessed. Based on the predefined reporting convention in the SAP, summary statistics describing variability (standard deviation/geometric coefficient of variation) were not calculated or presented for analysis groups or timepoints if fewer than 3 participants had reportable parameter values. |
Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D1 and C1D15, and an additional sample at 24 hours post dose on C1D1 for palbociclib 125 mg arms.
|
|
Part C: Accumulation Ratio for Cmax (Rac [Cmax]) of Vepdegestrant, Its Epimer ARV-473 and Palbociclib
Tidsramme: Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D1 and C1D15, and an additional sample at 24 hours post dose on C1D1 for palbociclib 125 mg arms.
|
Rac was calculated as the ratio of Day 15/Day 1 based on Cmax. Cmax was defined as the maximum observed plasma concentration obtained directly from the observed concentration versus time data. As planned for Part C, PK data of vepdegestrant and ARV-473 and palbociclib for arms administered with 125 mg palbociclib was reported for C1D1 and C1D15. As prespecified, participants in the Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 100 mg Arm were not assessed. Based on the predefined reporting convention in the SAP, summary statistics describing variability (standard deviation/geometric coefficient of variation) were not calculated or presented for analysis groups or timepoints if fewer than 3 participants had reportable parameter values. |
Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D1 and C1D15, and an additional sample at 24 hours post dose on C1D1 for palbociclib 125 mg arms.
|
|
Part C: Effective Half-life Based on Accumulation Ratio of RAUC(0-tau) (Effective T1/2) of Vepdegestrant, Its Epimer ARV-473 and Palbociclib
Tidsramme: Pre-dose, 1, 2, 4, 6, 8, 12, 24 hours post dose on C1D15 for arms with palbociclib 125 mg (each cycle is of 28 days)
|
Effective half-life based on accumulation ratio of RAUC(0-tau). Accumulation ratio was calculated as the ratio of Day 15/Day 1 based on AUCtau. AUCtau was defined as area under the concentration-time curve during a dosing interval calculated by linear up/log down trapezoidal summation. As planned for Part C, PK data of vepdegestrant and ARV-473 and palbociclib for arms administered with 125 mg palbociclib was reported for C1D1 and C1D15. Based on the predefined reporting convention in the SAP, summary statistics describing variability (standard deviation/geometric coefficient of variation) were not calculated or presented for analysis groups or timepoints if fewer than 3 participants had reportable parameter values. |
Pre-dose, 1, 2, 4, 6, 8, 12, 24 hours post dose on C1D15 for arms with palbociclib 125 mg (each cycle is of 28 days)
|
|
Part C: Epimer (ARV-473) to Parent (Vepdegestrant) Compound Molar Ratio for Cmax (MRCmax)
Tidsramme: Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D1 and C1D15, and an additional sample at 24 hours post dose on C1D1 for palbociclib 125 mg arms. Pre-dose, 1, 2, 4, 6, 8 hours post dose on C1D21/C2D15 for palbociclib 100 mg arms.
|
Epimer ARV-473 to parent ratio based on Cmax was reported. Cmax was defined as the maximum observed plasma concentration obtained from the observed concentration versus time data. As planned for Part C, PK data of vepdegestrant, ARV-473 and palbociclib for arms administered with 125 mg palbociclib was reported for C1D1/C1D15. PK data of vepdegestrant and ARV-473 data for arm administered with 100 mg palbociclib was reported for combined C1D21/C2D15. As per protocol, in 100 mg palbociclib administered arm, intensive PK sample collection not done on C1D21 was postponed to C2D15. Only combined data on C1D21 and C2D15 represented all the data at the steady state of the combination of vepdegestrant 200 mg QD with palbociclib and were used for DDI evaluation. Based on predefined reporting convention in the SAP, summary statistics were not calculated or presented for analysis groups or timepoints if fewer than 3 participants had reportable parameter values. |
Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D1 and C1D15, and an additional sample at 24 hours post dose on C1D1 for palbociclib 125 mg arms. Pre-dose, 1, 2, 4, 6, 8 hours post dose on C1D21/C2D15 for palbociclib 100 mg arms.
|
|
Part C: Epimer (ARV-473) to Parent (Vepdegestrant) Compound Molar Ratio for AUCtau (MRAUCtau)
Tidsramme: Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D1 and C1D15, and an additional sample at 24 hours post dose on C1D1 for palbociclib 125 mg arms. Pre-dose, 1, 2, 4, 6, 8 hours post dose on C1D21/C2D15 for palbociclib 100 mg arms.
|
Epimer ARV-473 to parent ratio based on AUCtau was reported. AUCtau was calculated by linear up/log down trapezoidal summation. As planned for Part C, PK data of vepdegestrant and ARV-473 and palbociclib for arms administered with 125 mg palbociclib was reported for C1D1 and C1D15. PK data of vepdegestrant and ARV-473 data for arm administered with 100 mg palbociclib was reported for combined C1D21 and C2D15. As per protocol, in the arm administered with 100 mg palbociclib, if the intensive PK sample collection was not done on C1D21, it was postponed to C2D15. Only combined data on C1D21 and C2D15 represented all the data at the steady state of the combination of vepdegestrant 200 mg QD with palbociclib and were used for DDI evaluation. Based on predefined reporting convention in the SAP, summary statistics were not calculated or presented for analysis groups or timepoints if fewer than 3 participants had reportable parameter values. |
Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D1 and C1D15, and an additional sample at 24 hours post dose on C1D1 for palbociclib 125 mg arms. Pre-dose, 1, 2, 4, 6, 8 hours post dose on C1D21/C2D15 for palbociclib 100 mg arms.
|
|
Part C: Overall Response Rate (ORR) by Investigator Per RECIST v1.1
Tidsramme: From start of study treatment until disease progression or death due to any cause (up to approximately 3 years and 9 months)
|
ORR was defined as the percentage of participants with BOR of CR and PR as per RECIST version [v] 1.1. BOR: best response was recorded from start of study treatment until disease progression or death due to any cause. CR was defined as disappearance of all TLs and non-TLs and normalization of tumor marker levels initially above upper limits of normal. PR was defined as >30% decrease in the sum of the LD of TLs, taking as reference the baseline sum LD. PD: >20% increase in the sum of the LD of TLs, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non-TLs. Only participants with measurable disease at baseline were included in the analysis of ORR. |
From start of study treatment until disease progression or death due to any cause (up to approximately 3 years and 9 months)
|
|
Part C: Clinical Benefit Rate (CBR)
Tidsramme: From start of study treatment until disease progression or death due to any cause (up to approximately 3 years and 9 months)
|
CBR: percentage of participants with summation of CR, PR or SD of 24 weeks duration or longer. CR: disappearance of all TLs and non-TLs and normalization of tumor marker levels initially above upper limits of normal. PR: >30% decrease in the sum of the LD of TLs, taking as reference the baseline sum LD. SD of TLs was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started. SD of non-TLs Persistence of one or more non-TLs or/and maintenance of tumor marker level above the normal limits. PD: >20% increase in the sum of the LD of TLs, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non-TLs. |
From start of study treatment until disease progression or death due to any cause (up to approximately 3 years and 9 months)
|
|
Part C: Progression-Free Survival (PFS) Per RECIST v1.1
Tidsramme: From start of study treatment up to progressive disease or death (up to approximately 3 years and 9 months)
|
PFS: time from first dose of the study drug until date of documented radiological PD based on RECIST V1.1, or until death due to any cause, whichever occurred first. PD: >20% increase in the sum of the LD of TLs, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non-TLs. KM estimate was used for analysis. |
From start of study treatment up to progressive disease or death (up to approximately 3 years and 9 months)
|
|
Part C: Overall Survival
Tidsramme: From start of study treatment up to death (up to approximately 3 years and 9 months)
|
OS was defined as the time from first dose of the study drug until the documented date of death from any cause. KM estimate was used for analysis. |
From start of study treatment up to death (up to approximately 3 years and 9 months)
|
|
Part C: Duration of Response
Tidsramme: From the date of first documented confirmed CR/PR to the date of PD or death due to any cause (up to approximately 3 years and 9 months)
|
DOR was defined as the time interval from the date of first documented confirmed CR/PR to the date of PD or death, whichever occurred first per RECIST version v 1.1. CR: disappearance of all TLs and non-TLs and normalization of tumor marker levels initially above upper limits of normal. PR: >30% decrease in the sum of the LD of TLs, taking as reference the baseline sum LD. PD: >20% increase in the sum of the LD of TLs, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non-TLs. KM estimate was used for analysis. |
From the date of first documented confirmed CR/PR to the date of PD or death due to any cause (up to approximately 3 years and 9 months)
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Samarbejdspartnere
Samarbejdspartnere
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Faktiske)
Primær færdiggørelse
Studieafslutning (Faktiske)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- ARV-471-mBC-101
- C4891019 (Anden identifikator: Pfizer)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .